Valuation : Natera, Inc.

Market Cap 46.41B 39.96B 37.52B 34.25B 64.34B 4,416B 64.8B 445B 173B 2,239B 174B 170B 7,414B P/E 2026 *
-235x
P/E 2027 * -37,437x
Enterprise Value 45.34B 39.04B 36.66B 33.46B 62.86B 4,314B 63.31B 434B 169B 2,188B 170B 167B 7,243B EV / Sales 2026 *
15.6x
EV / Sales 2027 * 12.9x
Free-Float
97.12%
Yield 2026 *
-
Yield 2027 * -
1 day-1.32%
1 week-1.76%
Current month+20.24%
1 month+20.24%
3 months+47.14%
6 months+55.51%
Current year+40.54%
1 week 316
Extreme 316
343.18
1 month 259.8
Extreme 259.8
343.18
Current year 181
Extreme 181
343.18
1 year 157.42
Extreme 157.425
343.18
3 years 36.9
Extreme 36.9
343.18
5 years 26.1
Extreme 26.1
343.18
10 years 7.35
Extreme 7.35
343.18
Manager TitleAgeSince
Chief Executive Officer 47 2019-01-01
President 46 2023-08-31
Director of Finance/CFO 45 2017-01-31
Director TitleAgeSince
Chairman 53 2015-04-30
Director/Board Member 53 2006-12-31
Director/Board Member 47 2019-01-01
Date Insider Type Main position Quantity % Market Cap. Importance
8/10/26 Sell

Founder

-6,000 0.0042%
8/10/26 Sell

Chairperson

-6,517 0.0046%
8/7/26 Sell

Founder

-2,000 0.0014%
Change 5-day change 1-year change 3-year change Capi.($)
-1.32%-1.76%+90.13%+448.20% 46.41B
-0.73%-1.97%+19.67%+59.86% 26.98B
-0.28%-8.89%-18.57%-39.26% 6.93B
+1.62%+1.51%+7.84%+126.94% 5.97B
-1.71%+0.98%+16.27%+74.84% 3.4B
-1.77%-0.45%-33.84%+1,805.84% 2.53B
-0.78%+9.14%+103.29%+19.16% 2.3B
+5.35%+5.98%+28.04%+33.33% 2.07B
-0.15%-12.66%-14.30%-55.06% 1.89B
-1.07%-10.61%+1.71%-18.64% 1.68B
Average -0.08%-0.64%+20.02%+245.52% 10.01B
Weighted average by Cap. -0.76%-1.28%+48.65%+276.60%

Financials

2026 *2027 *
Net sales 2.91B 2.5B 2.35B 2.14B 4.03B 276B 4.06B 27.83B 10.83B 140B 10.91B 10.67B 464B 3.48B 3B 2.81B 2.57B 4.82B 331B 4.86B 33.34B 12.97B 168B 13.07B 12.78B 556B
Net income -193M -166M -156M -142M -267M -18.36B -269M -1.85B -719M -9.31B -724M -709M -30.82B 9.13M 7.86M 7.38M 6.74M 12.65M 869M 12.75M 87.45M 34.02M 440M 34.27M 33.53M 1.46B
Net Debt -1.07B -920M -864M -788M -1.48B -102B -1.49B -10.23B -3.98B -51.54B -4.01B -3.92B -171B -1.36B -1.17B -1.1B -1.01B -1.89B -130B -1.9B -13.06B -5.08B -65.77B -5.12B -5.01B -218B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
26-08-31 US$321.96 -1.32% 1,326,118
26-08-28 US$326.26 -3.67% 833,869
26-08-27 US$338.70 +0.07% 731,371
26-08-26 US$338.45 +0.52% 1,094,667
26-08-25 US$336.71 +2.74% 1,733,153
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
321.96USD
Average target price
336.74USD
Spread / Average Target
+4.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock